ConductScience.org, home

Paper12552003

Developing novel oncolytic adenoviruses through bioselection.

Yan W and 12 others. J Virol, 2003. Cited by 41 papers, by iCite.

Cite this record

ConductScience Library. Developing novel oncolytic adenoviruses through bioselection. Papers, record 12552003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12552003

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Developing novel oncolytic adenoviruses through bioselection.
PubMed
Journal
J Virol
PubMed
Year
2003
PubMed
Publication types
Evaluation Study, Journal Article
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
0.9
iCite
Revised in PubMed
2019-12-10
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yan WWen
2Kitzes GGalila
3Dormishian FFarid
4Hawkins LLynda
5Sampson-Johannes AAdam
6Watanabe JJosh
7Holt JJenny
8Lee VVivian
9Dubensky TThomas
10Fattaey AAli
11Hermiston TTerry
12Balmain AAllan
13Shen YYuqiao

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adenoviruses, HumanMajor topic
Selection, GeneticMajor topic
Cytopathogenic Effect, Viral
Humans
Mutagenesis
Serial Passage
Tumor Cells, Cultured
Virology
Virus Replication

Source PubMed

Download CSV of topics

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16823011Sequence arrangement and protein coding capacity of the adenovirus type 2 "i" leader.J Virol1983https://conductscience.org/library/papers/6823011PubMed
210888838Replicative adenoviruses for cancer therapy.Nat Biotechnol2000https://conductscience.org/library/papers/10888838PubMed
311433341Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.Nat Med2001https://conductscience.org/library/papers/11433341PubMed
412086848Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents.Cancer Cell2002https://conductscience.org/library/papers/12086848PubMed
510837552Conditionally replicative adenoviruses for cancer therapy.Adv Drug Deliv Rev1997https://conductscience.org/library/papers/10837552PubMed
611313807Expansion of tropism of a feline parvovirus to target a human tumor cell line by display of an alpha(v) integrin binding peptide on the capsid.Gene Ther2001https://conductscience.org/library/papers/11313807PubMed
711208818Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.J Clin Oncol2001https://conductscience.org/library/papers/11208818PubMed
811393279A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.Cancer Gene Ther2001https://conductscience.org/library/papers/11393279PubMed
98828146Molecular evolution of aphthoviruses.Virus Genes1995https://conductscience.org/library/papers/8828146PubMed
1010741699A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.Clin Cancer Res2000https://conductscience.org/library/papers/10741699PubMed
117585090Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates.Nat Med1995https://conductscience.org/library/papers/7585090PubMed
127749317Viruses and apoptosis.Curr Opin Genet Dev1995https://conductscience.org/library/papers/7749317PubMed
1314329143ISOLATION OF TEMPERATURE-SENSITIVE MUTANTS OF POLYOMA VIRUS.Virology1965https://conductscience.org/library/papers/14329143PubMed
141457005The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins.Proc Natl Acad Sci U S A1992https://conductscience.org/library/papers/1457005PubMed
1510644974A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.Oncogene2000https://conductscience.org/library/papers/10644974PubMed
1610932190Molecular breeding of viruses.Nat Genet2000https://conductscience.org/library/papers/10932190PubMed
1711313778Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?Gene Ther2001https://conductscience.org/library/papers/11313778PubMed
182459413Evidence for two points of restriction in the expression of adenovirus type 2 in cultured epidermal keratinocytes.J Virol1988https://conductscience.org/library/papers/2459413PubMed
193005630Biosynthesis and properties of the adenovirus 2 L1-encoded 52,000- and 55,000-Mr proteins.J Virol1986https://conductscience.org/library/papers/3005630PubMed
204627331Selection and preliminary characterization of temperature-sensitive mutants of type 5 adenovirus.J Virol1972https://conductscience.org/library/papers/4627331PubMed

See all 51 referencesDownload CSV of references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
41716467Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD.Mol Ther Oncol2026https://conductscience.org/library/papers/41716467PubMed
39772264Optimized Directed Virus Evolution to Accelerate the Generation of Oncolytic Coxsackievirus B3 Adapted to Resistant Colorectal Cancer Cells.Viruses2024https://conductscience.org/library/papers/39772264PubMed
38664647Fast Track Adaptation of Oncolytic Coxsackie B3 Virus to Resistant Colorectal Cancer Cells - a Method to Personalize Virotherapy.Biol Proced Online2024https://conductscience.org/library/papers/38664647PubMed
34373477A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation.Sci Rep2021https://conductscience.org/library/papers/34373477PubMed
34040797Experimental virus evolution in cancer cell monolayers, spheroids, and tissue explants.Virus Evol2021https://conductscience.org/library/papers/34040797PubMed
33167307Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses.Biomedicines2020https://conductscience.org/library/papers/33167307PubMed
33103620A mutation in C. neoformans mitochondrial NADH dehydrogenase results in increased virulence in mice.Virulence2020https://conductscience.org/library/papers/33103620PubMed
32340119Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.Cancers (Basel)2020https://conductscience.org/library/papers/32340119PubMed
31694943Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.J Virol2020https://conductscience.org/library/papers/31694943PubMed
27999391Adenovirus with DNA Packaging Gene Mutations Increased Virus Release.Viruses2016https://conductscience.org/library/papers/27999391PubMed
27314377Development of an Oncolytic Adenovirus with Enhanced Spread Ability through Repeated UV Irradiation and Cancer Selection.Viruses2016https://conductscience.org/library/papers/27314377PubMed
25010337Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells.PLoS One2014https://conductscience.org/library/papers/25010337PubMed
24503714Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.PLoS One2014https://conductscience.org/library/papers/24503714PubMed
24434571The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.Cancer Gene Ther2014https://conductscience.org/library/papers/24434571PubMed
22312363Oncolytic viruses: the power of directed evolution.Adv Virol2012https://conductscience.org/library/papers/22312363PubMed
22140489Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis.PLoS One2011https://conductscience.org/library/papers/22140489PubMed
22011643A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction.Gene Ther2012https://conductscience.org/library/papers/22011643PubMed
21994711Increasing the efficacy of oncolytic adenovirus vectors.Viruses2010https://conductscience.org/library/papers/21994711PubMed
21863000Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.Mol Ther2012https://conductscience.org/library/papers/21863000PubMed
21477385Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells.Virol J2011https://conductscience.org/library/papers/21477385PubMed

See all 26 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12552003

GET https://conductscience.org/api/papers/v1/12552003/references?page=2